Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled dose-comparison study of BG00012 in relapsing-remitting multiple sclerosis
NL-OMON31459Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dimethyl fumarate in multiple sclerosis (MS) (3 arms), sponsored by Biogen. Primary endpoints: Proportion of subjects relapsed at 2 years and Time to first relapse. Started Nov 2008; status: active, not recruiting.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON31459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31459.